原发性慢速凝固经巩膜睫状体光凝激光治疗药物难治性新生血管性青光眼
回顾性研究纳入53例无既往切开性青光眼或睫状体光凝手术史的新生血管性青光眼患者,接受慢速凝固连续波经巩膜睫状体光凝(1250毫瓦功率、4秒持续时间)。眼压从术前40.7±8.6 mmHg降至术后18.4±12.2 mmHg(p<0.001),12和24个月累积成功概率分别为71.7%和64.2%,视力相对不变(p=0.618)。
要点
- 眼压从术前40.7±8.6 mmHg降至术后18.4±12.2 mmHg(p<0.001)。
- 青光眼药物从基线3.3±1.1种降至末次随访2.0±1.5种(p<0.001)。
- 12和24个月累积成功概率分别为71.7%和64.2%。
核心结论
- 慢速凝固经巩膜睫状体光凝是药物未控制的新生血管性青光眼有效且相对安全的初始手术干预。
研究设计与样本
- 回顾性研究纳入53例新生血管性青光眼患者,平均年龄69.6±16.6岁,平均随访12.7±8.9个月,均无既往切开性青光眼或睫状体光凝手术史。
- 所有患者接受慢速凝固连续波经巩膜睫状体光凝,功率1250毫瓦、持续时间4秒。
主要发现
- 眼压从术前40.7±8.6 mmHg降至术后18.4±12.2 mmHg(p<0.001)。
- 青光眼药物数量从基线3.3±1.1种降至末次术后随访2.0±1.5种(p<0.001)。
- 12和24个月累积成功概率分别为71.7%和64.2%。
- 平均最小分辨角对数视力从2.27±0.63至末次随访2.25±0.66相对不变(p=0.618)。
- 最常见并发症为基线视力下降(13.2%)和前房炎症(9.4%)。
关键数值与推荐
- 手术成功定义为眼压6至21 mmHg且较基线降低≥20%,无需因青光眼再手术,且无光感视力丧失。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To report treatment outcomes of slow-coagulation continuous-wave transscleral cyclophotocoagulation (TSCPC) as an initial surgical intervention in patients with neovascular glaucoma (NVG). METHODS: A retrospective study including 53 patients (mean age of 69.6±16.6 years and mean follow-up of 12.7±8.9 months) with a diagnosis of NVG and no previous incisional glaucoma or cyclophotocoagulation surgeries. All patients underwent slow-coagulation continuous-wave TSCPC (1250-milliwatt power and 4-second duration).Primary outcome measure was surgical success defined as an intraocular pressure (IOP) from 6 to 21 mm Hg with a reduction ≥20% from baseline, no reoperation for glaucoma and no loss of light perception vision. Secondary outcome measures include IOP, glaucoma medications, visual acuity (VA) and complications. RESULTS: IOP decreased from 40.7±8.6 mm Hg preoperatively to 18.4±12.2 mm Hg postoperatively (p<0.001). The preoperative number of glaucoma medications dropped from 3.3±1.1 at baseline to 2.0±1.5 at the last postoperative visit (p<0.001). The cumulative probabilities of success at 12 and 24 months were 71.7% and 64.2 %, respectively. Mean logarithm of the minimum angle of resolution VA was relatively unchanged from 2.27±0.63 to 2.25±0.66 at the last follow-up visit (p=0.618). The most common observed complications were decrease in baseline VA (13.2%) and anterior chamber inflammation (9.4%). CONCLUSIONS: Slow-coagulation TSCPC is an effective and relatively safe initial surgical intervention in medically uncontrolled NVG.
引用
- Khodeiry MM, Lauter AJ, Sayed MS, et al. Primary slow-coagulation transscleral cyclophotocoagulation laser treatment for medically recalcitrant neovascular glaucoma. Br J Ophthalmol. 2021. PMID: 34848391. doi:10.1136/bjophthalmol-2021-319757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。